2000 liver cancer patients studied to uncover best Pre-Surgery treatments
NCT ID NCT06405321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China. Researchers want to find out which treatments given before surgery (called conversion or neoadjuvant therapy) work best to help patients live longer. The study includes treatments like chemotherapy directly into the liver, targeted drugs, and immunotherapy. It does not test new treatments but instead analyzes past results to guide future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jian-Hong Zhong
RECRUITINGNanning, China, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?